How the Use of non-Registrational Evidence by Medical Affairs Improves Patient Outcomes

A White Paper by the Medical Affairs Professional Society (MAPS) Executive Consortium

A White Paper by the Medical Affairs Professional Society (MAPS) Executive Consortium

A White Paper by the Medical Affairs Professional Society (MAPS) Executive Consortium

GOLDEN, COLO, USA, September 21, 2021 /EINPresswire.com/ — In the biopharmaceutical industry, the organization’s Research and Development (R&D) function manages a program including Phase 1-3 clinical trials that leads to regulatory approval. Concurrently and continuing after approval, Medical Affairs manages a program to answer questions not addressed in the regulatory filing, but that remain essential in helping healthcare providers and others within the healthcare ecosystem optimize patient benefit. Will the drug work in patient populations beyond the narrowly defined clinical trial inclusion criteria? What about in patients with comorbidities? Or those taking other medications? How could an understanding of the natural history of a disease improve care paths and disease management? How do factors such as burden of disease and quality of life impact the decisions of payors and Health Technology Assessment (HTA) bodies, and what are the impacts on Healthcare Resource Utilization (HCRU)?

Answering these questions requires identifying/generating and interpreting non-Registrational Evidence (nRE). Very basically, the goal of nRE is to provide a framework for understanding how a drug functions in patient populations and real-world situations beyond those addressed in the regulatory filing. Along with the evidence from clinical development, nRE is included in the organization’s cross-functional Integrated Evidence Plan (IEP).

A white paper by the Medical Affairs Professional Society (MAPS) Executive Consortium published today details the sources, uses and benefits to the organization, to society and to patients of nRE, and describes why Medical Affairs – as the bridge between the organization and external stakeholders – is uniquely positioned to lead and own the strategic plan for the generation and use of nRE.

Read the Full Paper Here

Authors:
Karen Atkin, Senior Vice President BioPharmaceuticals Medical, AstraZeneca
Catrinel Galateanu, VP, Head of Global Medical Affairs, UCB
Charlotte Kremer, EVP, Head of Medical Affairs, Astellas
Sandra Silvestri, Senior Vice President & Global Head of Medical General Medicine, Sanofi
Doug Williamson, Senior Vice President and Head, US R&D and Global Chief Medical Officer (Deputy), Lundbeck

About MAPS
MAPS is the premier nonprofit global Medical Affairs organization for Medical Affairs professionals by Medical Affairs professionals across all different levels of experience/specialty to engage, empower, and educate. Together with more than 6,300 Medical Affairs members from more than 220 companies globally, MAPS is transforming the Medical Affairs profession to increase its value to patients, HCPs, and other decision-makers.

Garth Sundem
Medical Affairs Professional Society (MAPS)
+1 8055592023
email us here
Visit us on social media:
LinkedIn


Source: EIN Presswire